Antioxidant therapy prevents devastating vision loss when added to standard-of-care on rare birth defect

February 5, 2018 by Ellen Goldbaum, University at Buffalo
Light microscopy images of retinas from animal model of Smith-Lemli-Opitz Syndrome (SLOS). Treatment with antioxidant combination therapy (right) preserved normal retinal structure and prevented degeneration and death of photoreceptor cells (rods and cones). Credit: Steven Fliesler

A new study led by vision researchers at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and VA Western New York Healthcare System has demonstrated that the addition of widely available antioxidants to the current standard-of-care prevented vision loss in an animal model of a rare genetic disease.

Published in the Jan. 19 issue of Scientific Reports, the paper describes the that resulted in preventing the that can occur in babies born with Smith-Lemli-Opitz Syndrome (SLOS).

Caused by the body's inability to make cholesterol, the disease is a birth defect that results in multiple neurosensory and cognitive abnormalities, physical deformities and disabilities, including . In severe cases, it can be fatal.

"Using our combination therapy approach, we were able to prevent otherwise progressive and irreversible retinal degeneration from occurring in a of this hereditary human metabolic disease that we had previously developed," said Steven J. Fliesler, Ph.D., Meyer H. Riwchun Endowed Chair Professor, vice chair and director of research in the Department of Ophthalmology at the Jacobs School and Ira G. Ross Eye Institute Vision Research Center, and professor in the Department of Biochemistry and Neuroscience Program. He also is a research career scientist at the VA Western New York Healthcare System.

To treat the condition, dietary supplementation with cholesterol is prescribed in addition to treating the individual conditions seen in babies with SLOS, ranging from those affecting the central nervous system (including the eyes) to the heart, lungs, gastrointestinal tract and genitourinary systems, as well as the musculoskeletal . However, Fliesler noted that outcomes from the supplementation vary widely.

"We hypothesized – based upon findings in the literature, including seminal work from my lab – gthat oxidation of a specific molecule (which happens to be the immediate precursor of cholesterol) was key to the disease mechanism," he explained. "We reasoned that blocking the oxidation with antioxidants should prevent or significantly reduce the severity of the retinal degeneration observed in the rodent model. That evidence-based, therapeutic approach worked."

The success of the approach suggests a similar type of combination therapy might also be effective with humans, but Fliesler cautioned that while promising, these results should not be extrapolated directly to humans.

"It is advisable to conduct additional preclinical studies using appropriate animal models of the , such as those we used in this study, in order to refine dosages and specific antioxidant combinations," he said. "Some emerging, highly potent antioxidants not yet approved for human use might in the future be appropriate to investigate a potential treatment for human SLOS patients."

Explore further: First proteomic analysis of birth defect demonstrates power of a new technique

Related Stories

First proteomic analysis of birth defect demonstrates power of a new technique

September 11, 2013
The first proteomic analysis of an animal model of a rare, sometimes deadly birth defect, Smith-Lemli-Opitz Syndrome (SLOS), has revealed that the molecular mechanisms that cause it are more complex than previously understood. ...

Scientist models Smith-Lemli-Opitz syndrome in adult stem cells

April 20, 2016
Studies performed by a Sanford Research scientist using an innovative stem-cell model for a fatal developmental disorder is the focus of a recent study published in Nature Medicine. Kevin Francis, Ph.D. uncovered unique cellular ...

Oxidative stress on the brain

August 24, 2017
Smith-Lemli-Opitz syndrome (SLOS) is a rare disease that occurs when patients inherit from both parents defects in the Dhcr7 gene, which encodes the last enzyme in the cholesterol biosynthesis pathway. A large portion of ...

Fruit fly breakthrough may help human blindness research

December 18, 2017
For decades, scientists have known that blue light will make fruit flies go blind, but it wasn't clear why. Now, a Purdue University study has found how this light kills cells in the flies' eyes, and that could prove a useful ...

New model for hard-to-study form of blindness paves way for future research

September 6, 2017
Macular degeneration is the leading cause of vision loss in older adults, but scientists have long struggled to study and replicate key elements of the disease in the lab. A study published in the Proceedings of the National ...

Gene therapy slows vision loss in mouse models of retinal degeneration

March 24, 2015
Researchers have developed an antioxidant gene therapy that slows cone-cell death and prolongs vision in mouse models of retinal degeneration.

Recommended for you

Researchers are one step closer to developing eye drops to treat age-related macular degeneration

July 19, 2018
Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).

An orange a day keeps macular degeneration away: 15-year study

July 12, 2018
A new study has shown that people who regularly eat oranges are less likely to develop macular degeneration than people who do not eat oranges.

Injectable electronics offer powerful new tool in understanding how retinal cells work

June 28, 2018
Charles Lieber and his group are rewriting the rules of how scientists study retinal cells, and they're doing it with a single injection.

Why the eye could be the window to brain degeneration such as Alzheimer's disease

June 26, 2018
Researchers from Queen's University Belfast have shown for the first time that the eye could be a surrogate for brain degeneration like Alzheimer's disease (AD).

Microglia protect sensory cells needed for vision after retinal detachment

June 18, 2018
A research team at Massachusetts Eye and Ear has shown that microglia, the primary immune cells of the brain and retina, play a protective role in response to retinal detachment. Retinal detachment and subsequent degeneration ...

161 genetic factors for myopia identified

June 15, 2018
The international Consortium for Refractive Error and Myopia (CREAM) recently published the largest-ever genetic study of myopia in Nature Genetics. Researchers from the Gutenberg Health Study at the Medical Center of Johannes ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.